Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zydus joins once-weekly DPP-4 inhibitor fray

This article was originally published in Scrip

Executive Summary

Zydus Cadila has received US FDA approval to initiate Phase I trials for its candidate long-acting dipeptidyl peptidase IV (DPP-4) inhibitor for type 2 diabetes, joining a clutch of firms already in the development fray in the field including Merck & Co and Takeda.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC023202

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel